Sugi Predict

Sugi Predict / Targets / ERBB2

ERBB2

Receptor tyrosine-protein kinase erbB-2 · P04626 · ERBB2 on Sugi Atlas →

251,444 patent compounds predicted against ERBB2, 179,734 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Mubritinib Mubritinib (SCHEMBL94943) 1.00 20/20
SCHEMBL95052 SCHEMBL95052 1.00 19/20
SCHEMBL138668 SCHEMBL138668 0.77 18/20
Cp-724714 Cp-724714 (SCHEMBL95109) 1.00 17/20
Lapatinib Lapatinib (SCHEMBL93590) 0.99 17/20
SCHEMBL25699 SCHEMBL25699 0.82 16/20
SCHEMBL24610 SCHEMBL24610 1.00 14/20
Pelitinib Pelitinib (SCHEMBL93756) 1.00 14/20
Pelitinib Pelitinib (SCHEMBL93757) 1.00 14/20
SCHEMBL25412 SCHEMBL25412 0.86 14/20
SCHEMBL26310 SCHEMBL26310 0.86 14/20
SCHEMBL114306 SCHEMBL114306 0.85 14/20
SCHEMBL25716 SCHEMBL25716 0.84 14/20
SCHEMBL25802 SCHEMBL25802 0.84 14/20
SCHEMBL23474 SCHEMBL23474 0.47 14/20
SCHEMBL24110 SCHEMBL24110 0.47 14/20
Lapatinib Lapatinib (SCHEMBL8100) 1.00 13/20
SCHEMBL24808 SCHEMBL24808 1.00 13/20
SCHEMBL25098 SCHEMBL25098 1.00 13/20
Dacomitinib Anhydrous Dacomitinib Anhydrous (SCHEMBL25637) 1.00 13/20

Clinical trials — most relevant to ERBB2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Overcoming Endocrine Resistance in Metastatic Breast Cancer PHASE3UNKNOWN
A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,) PHASE3COMPLETED
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer PHASE3UNKNOWN
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer PHASE3ACTIVE_NOT_RECRUITING
Neoadjuvant GW572016 to Treat Breast Cancer PHASE2COMPLETED
Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501） PHASE2RECRUITING
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer PHASE2RECRUITING
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma PHASE1/PHASE2COMPLETED
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer PHASE2COMPLETED
Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer PHASE2UNKNOWN
Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy PHASE2COMPLETED
Development of a Fluorescent Visualization System for Non-visible Lung Cancer Nodules PHASE2UNKNOWN
Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by a Study in Patients With Stage I-III HER2 Positive Breast Cancer PHASE1/PHASE2UNKNOWN
Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer PHASE2UNKNOWN
Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer PHASE1/PHASE2UNKNOWN
Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer PHASE2COMPLETED
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 PHASE1COMPLETED
Assessing the Immunogenicity of pING-hHER3FL PHASE1ACTIVE_NOT_RECRUITING
Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing PHASE1COMPLETED
Bevacizumab in Multiple Phase I Combinations PHASE1COMPLETED
Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma PHASE1COMPLETED
TGW211 for Click-Cleavable Imaging in HER2-Positive Cancers. EARLY_PHASE1RECRUITING
Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer nanRECRUITING
Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients nanUNKNOWN
Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis nanUNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System nanUNKNOWN
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
Prognostic Value of Her2neu and EGFR in Primary Ovarian High Grade Serous Carcinoma. nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a ERBB2 binder may also engage these)

ProteinNameSimilarity
O18735 — 1.000 O18735 →
Q60553 — 1.000 Q60553 →
P06494 — 1.000 P06494 →
P70424 — 0.997 P70424 →
ERBB3 Receptor tyrosine-protein kinase erbB-3 0.979 landscape →
Q5RB22 — 0.979 Q5RB22 →
Q61526 — 0.977 Q61526 →
Q62799 — 0.976 Q62799 →
P55245 — 0.976 P55245 →
EGFR Epidermal growth factor receptor 0.974 landscape →
Q01279 — 0.972 Q01279 →
Q91009 — 0.965 Q91009 →
NTRK1 High affinity nerve growth factor receptor 0.955 landscape →
Q9GZM7 — 0.952 Q9GZM7 →
O75051 — 0.951 O75051 →
Q91XD7 — 0.950 Q91XD7 →
ITGB5 Integrin beta-5 0.949 landscape →
Q4V7F2 — 0.949 Q4V7F2 →
Q3UFB7 — 0.949 Q3UFB7 →
O70309 — 0.948 O70309 →
O43374 — 0.947 O43374 →
P26013 — 0.947 P26013 →
Q6W4X9 — 0.946 Q6W4X9 →
C9J798 — 0.946 C9J798 →
P35739 — 0.946 P35739 →
O95294 — 0.946 O95294 →
Q96HD1 — 0.945 Q96HD1 →
Q8BQH6 — 0.945 Q8BQH6 →
P70206 — 0.945 P70206 →
P07942 — 0.945 P07942 →